Infection biomarkers in primary care patients with acute respiratory tract infections—comparison of Procalcitonin and C-reactive protein

Marc Meili¹, Alexander Kutz¹, Matthias Briel²,á, Mirjam Christ-Crain³, Heiner C. Bucher², Beat Mueller¹ and Philipp Schuetz²*

Abstract

Background: There is a lack of studies comparing the utility of C-reactive protein (CRP) with Procalcitonin (PCT) for the management of patients with acute respiratory tract infections (ARI) in primary care. Our aim was to study the correlation between these markers and to compare their predictive accuracy in regard to clinical outcome prediction.

Methods: This is a secondary analysis using clinical and biomarker data of 458 primary care patients with pneumonic and non-pneumonic ARI. We used correlation statistics (spearman’s rank test) and multivariable regression models to assess association of markers with adverse outcome, namely days with restricted activities and persistence of discomfort from infection at day 14.

Results: At baseline, CRP and PCT did not correlate well in the overall population ($r^2 = 0.16$) and particularly in the subgroup of patients with non-pneumonic ARI ($r^2 = 0.08$). Low correlation of biomarkers were also found when comparing cut-off ranges, day seven levels or changes from baseline to day seven. High baseline levels of CRP (>100 mg/dL, regression coefficient 1.6, 95 % CI 0.5 to 2.6, sociodemographic-adjusted model) as well as PCT (>0.5ug/L, regression coefficient 2.0, 95 % CI 0.0 to 4.0, sociodemographic-adjusted model) were significantly associated with larger number of days with restricted activities. There were no associations of either biomarker with persistence of discomfort at day 14.

Conclusions: CRP and PCT levels do not well correlate, but both have moderate prognostic accuracy in primary care patients with ARI to predict clinical outcomes. The low correlation between the two biomarkers calls for interventional research comparing these markers head to head in regard to their ability to guide antibiotic decisions.

Trial registration: Current Controlled Trials, ISRCTN73182671

Keywords: Procalcitonin, C-reactive protein, Acute respiratory tract infection, Primary care, Outcome

* Correspondence: schuetzph@gmail.com
1University Department of Medicine, Kantonsspital Aarau, Tellstrasse 5001, Aarau, Switzerland

© 2016 Meili et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Acute respiratory tract infections (ARIs) are the most common reason for antibiotic therapy in primary care [1, 2]. Yet, about 70 % of ARIs are treated with antibiotics, despite their mainly viral etiology [3]. As a consequence, antibiotic overuse results in increased antibiotic resistance, antibiotic-induced adverse events, and costs [4, 5]. A novel approach for more individualized and targeted antibiotic therapy is the use of blood biomarkers, such as C-reactive protein (CRP) or Procalcitonin (PCT) [6–8]. Several trials in primary care have shown that the use of one of these markers reduces antibiotic exposure, although head to head comparison trials are currently lacking [9–11]. A recent systematic search and meta-analysis found a total of four observational studies from primary care looking at CRP and PCT for their ability to predict pneumonic infiltrate, need for hospitalization, and diagnosis of group A streptococcus pharyngitis [9]. Also, previous observational studies compared the diagnostic performance of CRP and PCT in the hospital setting [12, 13] and in septic patients in the ICU setting [14, 15]. However, a comprehensive comparison analysis between these two markers in the primary care setting is currently lacking. Importantly, so far PCT protocols have been used mainly for management of hospitalized and intensive care patients due to the lack of high sensitive point of care tests (POCT). Recently, a sensitive POCT has been developed and may be increasingly used in primary care [16].

Herein, using data from a previous trial, our aim was to study how well CRP and PCT correlate, and their predictive value for outcome discrimination in a large-scale well-defined ARI cohort [17, 18].

Methods
Study design and setting
This predefined ancillary project included all patients with upper and lower ARI enrolled between December 2004 and April 2006 into the PARTI trial (Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care) [17]. Study details have been reported elsewhere [18]. In brief, 53 primary care physicians in northwest of Switzerland consecutively screened adults with symptoms of an ARI and, in their physician’s opinion in need of antibiotics, were randomized to either a PCT-guided approach to antibiotic therapy or to a standard approach where physicians were asked to adhere to current guidelines. The primary non-inferiority outcome was the number of days, during the first 14 days after baseline, where a patient’s activities were restricted by an ARI.

Selection of participants
All patients with the diagnosis of upper or lower RTI and the physician’s intention to prescribe antibiotics, based on evidence guidelines, were consecutively included. Exclusion criteria were antibiotic use within the previous 28 days, psychiatric disorders or inability to give written informed consent, not being available for follow-up, not being fluent in German, severe immunosuppression, cystic fibrosis, active tuberculosis, and the need for immediate hospitalization.

Classification of patients was standardized according to previously defined guidelines for the correct diagnosis of patients with ARI [18]. For these subgroup analyses we divided patients into three groups based on the initial evaluation by a primary care physician: upper ARI comprised patients with rhinosinusitis, pharyngitis/tonsillitis, and otitis media; lower non-pneumonic ARI comprised patients with common cold, tracheo-bronchitis, influenza, acute exacerbation of asthma or chronic obstructive pulmonary disease, and lower pneumonic ARI comprised patients with community-acquired pneumonia (CAP).

Biomarker measurement
Blood samples were collected from all recruited patients on admission and day seven in ethylenediaminetetraacetic acid (EDTA) tubes. PCT determinations were made using a centralized time-resolved amplified cryptate emission technology-based assay (Kryptor® PCT, Thermo Scientific Biomarkers [B · R · A · H · M · S AG], Hennigsdorf, Germany) with a 0.06 μg/L functional sensitivity [19]. CRP concentrations were determined by an enzyme immunoassay having a detection limit <5 mg/dL (EMIT; Merck Diagnostica, Zurich, Switzerland). For the purpose of comparing cut-off ranges, PCT and CRP were stratified in four corresponding groups each, namely for PCT <0.1 μg/L, 0.1–0.25 μg/L, >0.25–0.5 μg/L, and >0.5 μg/L, and for CRP ≤20 mg/dL, 21–50 mg/dL, >51–99 mg/dL, and ≥100 mg/dL, respectively, based on the use of these markers in previous antibiotic stewardship trials in the low acuity setting [2, 20, 21].

Outcomes
In line with the initial study protocol [18], the predefined primary endpoint was the number of days, within the first 14 days after baseline, during which a patient’s daily activities (work or recreation) were restricted by a respiratory tract infection. The secondary endpoint was persistence of discomfort from infection at day 14. Both endpoints were assessed by seven medical students, blinded to the goal and design of the study, by conducting standardized follow-up interviews by telephone at 14 and 28 days after baseline.

Statistical analysis
We used descriptive statistics including mean with standard deviation, median with interquartile range
(IQR), and frequencies to describe the populations, as appropriate.

Assessment of correlation between biomarkers was performed by Spearman’s rank correlation analysis and visualized with scatter-plots. We looked at correlations between continuous biomarker levels and across cut-off ranges as defined above. For biomarker kinetics, we defined the change from baseline to day seven and classified the relative change into 4 groups (decrease of <25 %, 25–50 %, 50-75 % and >75 %).

To investigate associations between initial biomarker levels and endpoints, we used linear and logistic regression analysis. We adjusted for sociodemographic characteristics (age, gender, existence of comorbidities and education level) and in a second model also for disease severity (e.g. days spent with restricted activities before randomization and antibiotic prescription). Analyses were performed in the overall ARI patient population and in subgroups of different ARI types (upper ARI, non-pneumonic lower ARI, and pneumonic lower ARI). We calculated sensitivity and specificity using different clinically established cut-offs as defined above.

Statistical t-Tests were carried out at a 5 % significance level. All statistical analyses were performed with STATA Version 12.1 (Stata Corp, College Station, TX, USA).

Results

Patient population

This study included a total of 458 patients with a median age of 45 years (60 % females). Forty percent (184 patients) had upper ARI, particularly acute rhinosinusitis and acute pharyngitis/tonsillitis. Lower non-pneumonic ARI was diagnosed in 45 % of patients with acute bronchitis being the pre-dominant diagnosis (28 %) and 15 % had pneumonic lower RTI, namely CAP. Chest X-ray was performed in 121 patients, in 23 % of non-pneumonic ARI and in 97 % of CAP patients with non-pneumonic and pneumonic LRTI. The median reported degree of discomfort on recruitment was 6 – 7 (on a scale of 0 – 10 with 0 meaning no discomfort at all). Additional baseline characteristics of the study population are summarized in Table 1.

Correlation between PCT and CRP in different ARIs

Figures 1 and 2 show correlations of CRP and PCT in the overall population, and stratified by subgroups at baseline and on day seven. At baseline, we found significant correlations with however a low correlation coefficient between the two markers in the overall study population ($r^2 = 0.16$), as well as in all subgroups. Highest correlations were found in the pneumonic lower ARI group ($r^2 = 0.34$). On day seven, there were again weak correlations between both biomarkers in the overall population as well as in the subgroups.

We also investigated correlation of markers across well-established cut-off ranges (Tables 2 and 3). At baseline, 42 % of patients were in similar cut-off ranges with 9 % of patients being in higher PCT ranges and 49 % in higher CRP ranges. For day seven, 76 % of patients were in similar cut-off ranges with 13 % of patients being in higher PCT ranges and 11 % in higher CRP ranges. Looking at kinetics found 11 % of patients had a similar decrease in biomarker level with 75 % of patients having a stronger CRP decrease and 9 % a stronger PCT decrease. An increase in biomarker level was observed in 5 % of patients.

Association of admission biomarker levels and adverse outcome

Table 4 summarizes the results of regression analyses investigating the association of initial biomarker levels and adverse outcomes, namely days with restricted activities and persistence of ongoing discomfort at day 14. Analyses were performed according to baseline and day seven.

### Table 1 Patient characteristics

|                      | All patients ($n=458$) |
|----------------------|------------------------|
| **Demographics**     |                        |
| Age (years) – median [IQR] | 45 (32–62)             |
| Female gender – n (%) | 273 (59.6 %)           |
| **Comorbidities**    |                        |
| Presence of any comorbidity – n (%) | 70 (15.3 %)  |
| **Final diagnosis**  |                        |
| Upper RTI            | 184 (40.2 %)           |
| Acute rhinosinusitis – n (%) | 104 (22.7 %)   |
| Acute pharyngitis/tonsillitis – n (%) | 75 (16.4 %)   |
| Acute otitis media – n (%) | 5 (1.1 %)       |
| Lower non-pneumonic RTI | 205 (44.8 %)         |
| Common cold – n (%)  | 31 (6.8 %)             |
| Acute bronchitis – n (%) | 140 (30.6 %)         |
| Influenza – n (%)    | 4 (0.9 %)              |
| Exacerbated COPD – n (%) | 21 (4.6 %)       |
| Exacerbated asthma – n (%) | 9 (2 %)             |
| Lower pneumonic RTI  | 69 (15.1 %)            |
| Medical outcome of patients |
| Days with restricted activities within 14 days – median [IQR] | 9 (6–12) |
| Persisting discomfort after 14 days | 208 (45.7 %) |
| Degree of discomfort (scale 1–10) – median [IQR] | 2 (1–5) |
| **Biomarkers**       |                        |
| CRP mg/dL median (SD) [IQR] | 31 (60) (8.3-72.7) |
| PCT μg/L median (SD) [IQR] | 0.08 (2.11) (0.05-0.11) |
biomarker levels. For CRP, we found levels >100 mg/dL to be significantly associated with days of restricted activities (coefficient: 1.6 (95 % CI: 0.5, 2.6), \( p = 0.005 \)). For day seven, results were similar with again levels >100 mg/dL being significantly associated in sociodemographically adjusted analysis (coefficient: 3.3 (95 % CI: 0.5, 6.2), \( p = 0.022 \)) and a trend in fully adjusted analysis. For PCT, only initial levels >0.5µg/L were significantly associated with days with restricted activities in sociodemographically adjusted analysis (coefficient 2.0, 95 % CI 0.0 to 4.0) with a trend after full adjustment (\( p = 0.089 \)).

We also repeated the same analysis in the different subgroups, i.e. in patients with upper ARI and in lower pneumatic and non-pneumatic ARI. While for the upper ARI no significant associations were found, best results were seen in the non-pneumonic lower ARI group (see Additional files 1, 2, 3, 4 and 5).

Finally, we also investigated associations of biomarkers with persistent discomfort after 14 days. For this endpoint, no significant associations were found for both markers at baseline. For the day seven analysis, significant results were found for CRP, but not PCT.

**Discussion**

The findings of this analysis including a large primary care population with different types of ARI are threefold.

First, correlations between CRP and PCT levels were low in the overall population and particularly in the upper and non-pneumonic lower ARI. Second, high levels of both markers in the highest cut-off range were associated with days with restricted activity but not with ongoing discomfort. Third, kinetics did not significantly improve outcome prediction.

To date, ARI still represent an important public health issue affecting millions of patients around the world. Incorrect or delayed diagnosis may directly lead to severe complications and increases morbidity and mortality, especially in the inpatient setting [3]. Sputum and blood cultures are commonly seen as the gold standard. Still, these techniques have low sensitivity and lack practicability (e.g. in case of non-productive cough) [22, 23]. Because differentiation of mild viral infection from more severe infections is challenging, clinicians often start empiric antibiotic treatment which increases resistance of common bacteria and causes drug-related side effects [24, 25]. In this context, objectively measurable blood biomarkers may help to assess severity and need for more intensive treatment. There is still uncertainty about optimal use of PCT or CRP in the primary care setting for the management of patients. Herein, our analysis including a large and well defined cohort of ARI patients sheds new light on this important topic.
Compared to higher acuity settings, patients with low acuity ARI had low PCT levels with minimal changes over seven days. Yet, CRP levels showed a higher variability. This is also consistent with findings from other primary care studies [26], suggesting that PCT is more specific to bacterial infections and low in patients with mainly viral infections, while CRP increases independent of infection type as a “inflammatory marker”.

**Fig. 2 a-c:** Correlation of Procalcitonin and CRP levels in lower and upper respiratory tract infections on day 7.
Table 2: Classification of biomarkers at baseline and day seven

| Biomarker | CRP < 20 | CRP 20-50 | CRP 50-100 | CRP > 100 | Total |
|-----------|----------|-----------|------------|-----------|-------|
| PCT < 0.1 | 141 | 82 | 62 | 15 | 300 |
|           | 47 % | 27.3 % | 20.7 % | 5 % | 100 % |
| PCT 0.1-0.25 | 38 | 34 | 25 | 33 | 130 |
|           | 29.2 % | 26.2 % | 19.2 % | 25.4 % | 100 % |
| PCT 0.25-0.5 | 0 | 1 | 1 | 3 | 5 |
|           | 0 % | 20 % | 20 % | 60 % | 100 % |
| PCT > 0.5 | 1 | 0 | 0 | 14 | 15 |
|           | 6.7 % | 0 % | 0 % | 93.3 % | 100 % |
| Total     | 180 | 117 | 88 | 65 | 450 |
|           | 40 % | 26 % | 19.6 % | 14.4 % | 100 % |

| Biomarker | CRP < 20 | CRP 20-50 | CRP 50-100 | CRP > 100 | Total |
|-----------|----------|-----------|------------|-----------|-------|
| PCT < 0.1 | 322 | 30 | 5 | 3 | 360 |
|           | 89.4 % | 8.3 % | 1.4 % | 0.8 % | 100 % |
| PCT 0.1-0.25 | 52 | 7 | 6 | 3 | 68 |
|           | 76.5 % | 10.3 % | 8.8 % | 4.4 % | 100 % |
| PCT 0.25-0.5 | 2 | 1 | 0 | 0 | 3 |
|           | 66.7 % | 33.3 % | 0 % | 0 % | 100 % |
| PCT > 0.5 | 1 | 0 | 1 | 1 | 3 |
|           | 33.3 % | 0 % | 33.3 % | 33.3 % | 100 % |
| Total     | 377 | 38 | 12 | 7 | 434 |
|           | 86.9 % | 8.8 % | 2.8 % | 1.6 % | 100 % |

Table 3: Classification of biomarkers at kinetics

| Biomarker | Increase (CRP) | Decrease (CRP) 0 - 25 % | Decrease (CRP) 25 - 50 % | Decrease (CRP) 50 - 75 % | Decrease (CRP) > 75 % | Total |
|-----------|----------------|-------------------------|-------------------------|-------------------------|-----------------------|-------|
| Increase (PCT) | 22 | 14 | 17 | 26 | 53 | 132 |
| Decrease (PCT) 0-25 % | 16.7 % | 10.6 % | 12.9 % | 19.7 % | 40.2 % | 100 % |
| Decrease (PCT) 25-50 % | 9.5 % | 7.1 % | 10.7 % | 11.9 % | 60.7 % | 100 % |
| Decrease (PCT) 50-75 % | 6.3 % | 5.3 % | 7.4 % | 17.9 % | 63.2 % | 100 % |
| Decrease (PCT) > 75 % | 2 | 2 | 5 | 9 | 66 | 84 |
| Total | 39 | 27 | 39 | 66 | 257 | 428 |
|       | 9.1 % | 6.3 % | 9.1 % | 15.4 % | 60.1 % | 100 % |
Table 4 Biomarker at baseline and day seven as predictor for days with restricted activities or persistence of discomfort after 14 days

| Days with restricted activities: coefficient (95 % CI) | Biomarker at baseline | Fully adjusted model | Demographic-adjusted model | Adjusted* |
|---------------------------------------------------|-----------------------|----------------------|-----------------------------|-----------|
| CRP (mg/dL)                                       | 0.4 (−0.2 to 0.9), p = 0.169 | 0.3 (−0.3 to 0.9), p = 0.324 | 0.7 (0.1 to 1.4), p = 0.035 | 0.6 (−0.1 to 1.3), p = 0.075 |
| CRP ≤20                                           | Reference group       | Reference group       | Reference group             | Reference group |
| CRP 20-50                                         | 0.4 (−0.5 to 1.3), p = 0.37 | 0.4 (−0.5 to 1.3), p = 0.407 | 0.7 (−0.6 to 2.0), p = 0.264 | 0.8 (−0.5 to 2.1), p = 0.252 |
| CRP 50-100                                        | 0.0 (−1.0 to 1.0), p = 0.956 | −0.1 (−1.0 to 0.9), p = 0.920 | 2.5 (0.3 to 4.7), p = 0.024 | 2.4 (0.2 to 4.5), p = 0.035 |
| CRP >100                                          | 1.6 (0.5 to 2.6), p = 0.005 | 1.4 (0.3 to 2.5), p = 0.014 | 3.3 (0.5 to 6.2), p = 0.022 | 2.7 (−0.3 to 5.7), p = 0.078 |
| PCT (μg/L)                                        | 0.9 (0 to 1.9), p = 0.048 | 0.8 (−0.2 to 1.8), p = 0.123 | 0.7 (−0.6 to 2.1), p = 0.297 | 0.5 (−0.9 to 1.9), p = 0.484 |
| PCT ≤0.1                                          | Reference group       | Reference group       | Reference group             | Reference group |
| PCT 0.1-0.25                                      | 0.4 (−0.4 to 1.2), p = 0.320 | 0.3 (−0.5 to 1.1), p = 0.407 | 0.6 (−0.4 to 1.6), p = 0.249 | 0.5 (−0.5 to 1.5), p = 0.353 |
| PCT 0.25-0.5                                      | 1.6 (−1.3 to 4.4), p = 0.288 | 1.2 (−1.8 to 4.1), p = 0.434 | 2.9 (−1.5 to 7.3), p = 0.194 | 2.3 (−2.1 to 6.7), p = 0.300 |
| PCT >0.5                                          | 2.0 (0.0 to 4.0), p = 0.045 | 1.8 (−0.3 to 3.8), p = 0.089 | −0.3 (−4.6 to 4.1), p = 0.900 | −0.7 (−5.1 to 3.7), p = 0.751 |

Persistence of discomfort after 14 days: coefficient (95 % CI)

| Biomarker at baseline | Demographic-adjusted model | Adjusted* |
|-----------------------|-----------------------------|-----------|
| CRP (mg/dL)           | 1.0 (0.8 to 1.4), p = 0.831 | 1.7 (1.2 to 2.4), p = 0.005 |
| CRP ≤20               | Reference group             | Reference group |
| CRP 20-50             | 1.2 (0.7 to 1.9), p = 0.517 | 1.6 (0.8 to 3.2), p = 0.203 |
| CRP 50-100            | 1.0 (0.6 to 1.8), p = 0.862 | 3.4 (0.9 to 13.1), p = 0.078 |
| CRP >100              | 1.2 (0.7 to 2.2), p = 0.477 | 6.4 (0.7 to 54.8), p = 0.091 |
| PCT (μg/L)            | 1.1 (0.6 to 1.7), p = 0.845 | 0.9 (0.4 to 1.9), p = 0.804 |
| PCT ≤0.1              | Reference group             | Reference group |
| PCT 0.1-0.25          | 0.8 (0.5 to 1.3), p = 0.439 | 1.1 (0.7 to 1.9), p = 0.655 |
| PCT 0.25-0.5          | 3.3 (0.6 to 18.0), p = 0.166 | 2.5 (0.2 to 28.5), p = 0.460 |
| PCT >0.5              | 1.6 (0.5 to 4.7), p = 0.402 | 0.5 (0.0 to 5.7), p = 0.540 |

Adjusted for: gender, comorbidities, years of education, randomization (*additional adjustment: prescription of antibiotics, days with RA prior to randomization)
Interestingly, as shown in our correlation analyses, patients displayed differences in biomarker profiles with low correlation between markers and between cut-off ranges. Because both markers had suboptimal prognostic accuracy for outcome prediction, and because no gold standard for ARI in need of antibiotics exist, only a head to head trial comparing the performance of both markers in regard to antibiotic management may help to clarify the question which marker is more helpful in the management of ARI patients.

Several limitations should be considered when interpreting our results. First, this is a secondary analysis of previous randomized study with a different study question, i.e., whether antibiotic therapy guided by PCT reduces the use of antibiotics without increasing the restrictions experienced by patients. Second, no external validation of ARI diagnoses was done. Instead, physicians were encouraged to use updated guidelines presented in an interactive seminar. Also, chest X-ray was not mandatory for diagnosis of CAP and some patients may have been misclassified. In addition, we classified patients with common cold, influenza, and acute laryngitis-bronchitis as lower ARI because they frequently presented with cough as a main symptom and pathological findings in chest auscultation. Third, we focused on adverse outcomes as specified in the original trials but did not look into other adverse outcomes such as unplanned readmission to the GP, hospital admission, and respiratory failure among others. Further, PCT was not measured on site, due to lack of sensitive POC at that time. Future studies comparing these markers should also look into POC system for both markers in primary care.

**Conclusion**

This is the first large and comprehensive study investigating correlations between CRP and PCT and their predictive value in the primary care setting in patients with different types of ARI. The low correlations between the two biomarkers and the only moderate prognostic accuracy calls for a head-to-head trial comparing the ability of both markers to manage primary care patients with ARI to answer the question which marker is superior.

**Ethics approval and consent to participate**

The ethics committee of the University Hospital Basel, Switzerland, approved the trial protocol. The trial was supervised by an independent monitoring board consisting of a general internist in primary care, an infectious disease specialist, and a pneumologist. All participating physicians and patients gave written informed consent.

**Consent for publication**

Not applicable.

**Availability of data and materials**

Due to our local Institutional review board policy, we do not have permission to make the data sets on which the conclusions of the paper rely publicly available. A truncated data set (removing all potentially identifying features) may be made available on an individual request basis.

**Additional files**

- **Additional file 1:** Subgroup classification at baseline. (PPTX 128 kb)
- **Additional file 2:** Subgroup classification on day seven. (PPTX 89 kb)
- **Additional file 3:** Biomarker at baseline and day seven as predictors for days with restricted activities or persistence of discomfort after 14 days according to subgroups. URTI. (PPTX 86 kb)
- **Additional file 4:** Biomarker at baseline and day seven as predictors for days with restricted activities or persistence of discomfort after 14 days according to subgroups. LRTI non-pneumonic. (PPTX 86 kb)
- **Additional file 5:** Biomarker at baseline and day seven as predictors for days with restricted activities or persistence of discomfort after 14 days according to subgroups. LRTI pneumatic. (PPTX 86 kb)

**Abbreviations**

ARII: acute respiratory tract infection; CAP: community acquired pneumonia; CRP: C-reactive protein; GP: general practitioner; LRTI: lower respiratory tract infection; PCT: procalcitonin; POCT: point of care test; RTI: respiratory tract infection; PARlTI: procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care.

**Competing interests**

No commercial sponsor had any involvement in design and conduct of this study; namely collection, management, analysis, and interpretation of the data; and preparation, decision to submit, review, or approval of the manuscript. Drs. Kutz, Christ-Crain, Mueller, and Schuetz, received support from BRAHMS to attend meetings and fulfilled speaking engagements. Drs. Schuetz, Christ-Crain and Mueller received support from bioMérieux to attend meetings and fulfilled speaking engagements. Dr. Mueller has served as a consultant and received research support from BRAHMS and bioMérieux. Dr. Briel and Bucher report grants from BRAHMS during the conduct of the study. All other authors declare that the answer to the questions on the competing interest form are all “No” and therefore have nothing to declare.

**Authors’ contributions**

Study concept and design: MB, MC, HB, PS; Acquisition of data: MB, FC, HB, PS; Analysis and interpretation of data: MM, PS; drafting of the manuscript: MM, PS; Critical revision of the manuscript for important intellectual content: AK, MB, MC, FC, HB, BM, PS. All authors read and approved the final manuscript.

**Acknowledgements**

We are grateful to the physicians, their staff and patients who participated in the study. We thank Fausta Chiaverio, Peter Huber, Jacqueline Canonica, Vener Wyss, Urs Duering, Christine Leuthard, Ursula Saner, Melanie Wieland, and the staff of the central laboratory of the University Hospital Basel for their assistance and technical support, Christian Schindler for providing the randomization scheme, Sabine Jährmann, Yves Sunier, Zoe Schumacher, Angelo Vivacqua, Tatjana Vlanc, Nadia Rossinelli, and Martina Viglino for conducting the telephone interviews, and Ferdinand Martius, Michael Gonon, and Werner Zimmerli of the Data Safety and Monitoring Board for their work.

**Funding/Support**

This investigator-initiated study was sponsored by a grant from the Swiss National Science Foundation (3300C0-107772) and by the Association for the Promotion of Science and Postgraduate Training of the University Hospital Basel. Brahms AG provided assay and kit material related to the study. Dr Briel, Mr Young and Dr Bucher are supported by Santésuisse, Solothurn, Switzerland, and the Gottfried and Julia Bangert-Rhyner-Foundation, Berne, Switzerland. Dr Schuetz, Mrs Schild, and Dr Christ-Crain were supported by...
funds of the Freiwillige Akademische Gesellschaft, the Department of Endocrinology, Diabetology and Clinical Nutrition, and the Department of Clinical Chemistry, all Basel, Switzerland.

**Author details**
1. University Department of Medicine, Kantonsspital Aarau, Tellstrasse 501, Aarau, Switzerland. 2. Basle Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, Basel, Switzerland. 3. Division of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Basel, Basel, Switzerland. 4. Department of Clinical Epidemiology and Biostatistics, Mclachlan University, Hamilton, Canada.

**Received:** 4 December 2015 **Accepted:** 15 March 2016 **Published online:** 24 March 2016

**References**
1. Goossens H, Ferech M, Vander Stichele R, Elseviers M, Group EP. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579–87.
2. Calis JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ. 2009;338:b1374.
3. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory tract infections in the community. Lancet. 1993;341(8844):511–4.
4. Schuetz P, Balk R, Briél M, Kutz A, Christ-Crain M, Stolz D, Boudadina L, Wolff M, Kristoffersen KB, Wei L, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med. 2015;53(4):583–92.
5. Johnson DM, Stillwell MG, Fritsch TR, Jones RN. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999–2003). Diagn Microbiol Infect Dis. 2006;56(1):69–74.
6. Schuetz P, Albirch W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti-Infect Ther. 2010;8(5):575–87.
7. Schuetz P, Auerjesky D, Muller C, Muller B. Biomarker-guided personalised emergency medicine for all - hope for another hype? Swiss Med Wkly. 2015;145:w4079.
8. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections-hope for hype? Swiss Med Wkly. 2009;139(23–24):318–26.
9. Meili M, Muller B, Kulkarni P, Schuetz P. Management of patients with respiratory infections in primary care: procalcitonin, C-reactive protein or both? Expert Rev Respir Med. 2015;9(5):587–601.
10. Schuetz P, Briél M, Christ-Crain M, Stolz D, Boudadina L, Wolff M, Luyt CE, Chastre J, Tubach F, Kristoffersen KB, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55(1):651–62.
11. Schuetz P, Muller B, Christ-Crain M, Stolz D, Tammin M, Boudadina L, Luyt CE, Wolff M, Chastre J, Tubach F, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;9, CD007498.
12. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, Nicholson KG, Brightling CE. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410–8.
13. Tang J, Long W, Yan L, Zhang Y, Xie J, Lu G, Yang C. Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial. BMC Infect Dis. 2013;13:596.
14. Su L, Han B, Liu C, Lian L, Jiang Z, Deng J, Yan P, Jia Y, Feng D, Xie L. Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis. 2012;12:157.
15. Garnacho-Montero J, Huici-Moreno MJ, Gutierrez-Pizarro A, Lopez I, Marquez-Vacaro JA, Macier H, Guerrero JM, Puppo-Moreno A. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. Crit Care. 2014;18(3):R116.
16. Kutz A, Hautfater P, Oppert M, Alan M, Gollmund E, Gatt C, Alonso C, Wissmann C, Kuehn C, Bernard M, et al. Comparison between B.R.A.H.M.S PCT direct, a new sensitive point-of-care testing device for rapid quantification of procalcitonin in emergency department patients, and established reference methods - a prospective multinational trial. Clin Chem Lab Med. 2015;54(4):577–84.
17. Briél M, Schuetz P, Mueller B, Young J, Schild U, Nusbaum C, Periat P, Bucher HC, Christ-Crain M. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008;168(18):2000–7. discussion 2007–2008.
18. Briél M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P, Bucher HC, Muller B. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]. BMC Fam Pract. 2005;6:34.
19. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tammm M, Muller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600–7.
20. van der Meer V, Neven AK, van den Broek PJ, Assendelft WJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ. 2005;331(7527):26.
21. Falk G, Fahey T. C-reactive protein and community-acquired pneumonia in ambulatory care: systematic review of diagnostic accuracy studies. Fam Pract. 2009;26(1):10–21.
22. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. Clin Microbiol Rev. 1997;10(3):444–65.
23. Garcia-Vazquez E, Marcos MA, Mensa J, De Roux A, Puig J, Font C, Francisco G, Torres A. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med. 2004;164(16):1807–11.
24. Albirch WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis. 2004;10(3):514–7.
25. Harbarth S, Albirch WC, Brun-Buisson C. Outpatient antibiotic use and prevalence of antibiotic-resistant pneumococci in France and Germany: a sociocultural perspective. Emerg Infect Dis. 2002;8(12):1460–7.
26. Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K, Hummers-Pradier E, Welte T. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010;36(3):601–7.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries.
- Our selector tool helps you to find the most relevant journal.
- We provide round the clock customer support.
- Convenient online submission.
- Thorough peer review.
- Inclusion in PubMed and all major indexing services.
- Maximum visibility for your research.

Submit your manuscript at www.biomedcentral.com/submit